Precio
GRÁFICO POR
Información
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
- Industrias
- Biotechnology
- Sector
- Sanidad
Identificador
- Número de Identificación Internacional de Valores (ISIN)
- DE000A0V9BC4